Can-Fite BioPharma Ltd.

Regulatory Filings • Feb 18, 2025

_________ false

��-���� ������� ��"�	2 381
CAN-FITE BIOPHARMA LTD
Corporation no: 512022153	14960
- - -

	Israel Securities Authority			Tel Aviv Stock Exchange		C003 ( Public )		Reported via MAGNA:	18/02/2025
	www.isa.gov.il			www.tase.co.il				Reference:	2025-02-011325	Time of broadcast: 11:30 11:30

---

The corporation scheduled the publication of the report to 18/02/2025 14:00Other Report or AnnouncementRegulation 5 of the Securities Regulations, (Periodic and Immediate Reports of Foreign Corporation) 5761-2000

	The corporation is a foreign private issuer as defined by U.S. Securities Laws.

Attached hereto is a report on	Disappearance of Decompensated Liver Cirrhosis Episodes After Treatment with Can-Fite�s Namodenoson. Liver cirrhosis treatment market is estimated to reach approximately $15 billion in the U.S. by 2030

ea023139701-6k_canfiteEDGAR1_Bannerless_isa.pdf

References of previous documents relating to this matter(the reference does not constitute incorporation by reference):
- - -
Stock Exchange/Market: -1	Date of revision of form structure: 06/08/2024
Address: Bareket 10 , Petach-Tikva 47190   , Tel: 03-9241114 , 03-9213501 Fax: 03-9249378
E-mail address: motti@canfite.co.il   Company site: www.canfite.com
Previous names of reporting entity:
Name of the Signatory: FARBSTEIN MORDECHAI Position of Signatory in the reporting corporation: Chief Operating Officer & CFO Name of Employer Company:
Address: Maharal street 10 , Tel Aviv 6248110 Telephone: 052-8998671 Facsimile: E-mail: Motti@canfite.co.il 1